- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast Edition
On this episode of Not So Different, we recap some of the biggest biosimilars news that happened over the past month, including updates on clinical trials for oncology biosimilars as well as a survey on whether patients were given adequate information prior to switching a biosimilar.
This week’s episode is going to be recapping some of the biggest biosimilars news that happened over the past month. Much of the month focused on biosimilars used to treat patients with different types of cancer as well as whether patients and providers are being given adequate information prior to switching patients from a reference product to a biosimilar.
Show notes
Written version of the roundup: https://www.centerforbiosimilars.com/view/biosimilars-oncology-roundup-july-2022
Phase 3 denosumab trial results: https://www.centerforbiosimilars.com/view/denosumab-biosimilar-demonstrates-noninferiority-to-prolia-in-postmenopausal-osteoporosis
Alvotech’s pharmacokinetics trial for denosumab: https://www.centerforbiosimilars.com/view/alvotech-to-launch-pharmacokinetics-study-for-denosumab-biosimilar
Poster from the American Society of Clinical Oncology’s annual meeting: https://www.centerforbiosimilars.com/view/posters-assess-quality-of-trastuzumab-denosumab-biosimilars-in-cancer
Phase 1 pertuzumab trial: https://www.centerforbiosimilars.com/view/henlius-pertuzumab-biosimilar-shows-similar-pk-profile-to-reference-product-in-first-human-study
Rituximab studies from the European Hematology Association Congress 2022: https://www.centerforbiosimilars.com/view/rituximab-biosimilars-prove-effective-in-large-b-cell-lymphoma
Survey on preparing patients and providers for switching to a biosimilar: https://www.centerforbiosimilars.com/view/survey-most-patients-received-inadequate-information-about-switching-to-a-trastuzumab-biosimilar
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
January 13th 2025The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.
